Galvanized by its successes in Covid, Pfizer is accelerating in respiratory diseases.
The world leader in the pharmaceutical industry buys the British biotech Reviral, which owns two drug candidates against respiratory syncytial syndrome (RSV), the virus at the origin of bronchiolitis in particular.
Its most advanced molecule, sisunatovir, is currently in phase II clinical development in infants.
The amount of the transaction could reach up to 525 million dollars.
To discover
LIVE - Presidential 2022: follow the first round of the election
Presidential 2022: find here the result of the first round of the election from Sunday evening
Read also
Pfizer grants licenses for the manufacture of generic anti-Covid treatments
A great exit for Andera Partners (formerly Edmond de Rothschild Investment Partners), one of the main European players in private equity, the largest shareholder in Reviral since 2015, which has invested around twenty million dollars in seven years (on the $120 million raised in total by Reviral).
Co-lead in the first round of financing of 21 million dollars in 2015, he then reinvested twice alongside international investors…
This article is for subscribers only.
You have 62% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login
